Overview

Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial

Status:
RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to evaluate the change in glycated hemoglobin (HbA1c) levels of adding cofrogliptin compared to escalation of metformin dose after 24 weeks in type 2 diabetes patients who have failed to achieve adequate glycemic control despite receiving combination therapy with SGLT2i and metformin. Participants will be asked to use either cofrogliptin combined with SGLT2i and metformin or SGLT2i combined with increased dose of metformin.

Phase:

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators:

Hangzhou Traditional Chinese Medicine Hospital
Ningbo Medical Center Lihuili Hospital
The Second Affiliated Hospital of Dalian Medical University
Wenzhou Central Hospital